Stiftung Charité and the Berlin Institute of Health (BIH) are supporting the establish-ment of
UP TO 4 BIH JOHANNA QUANDT PROFESSORSHIPS
– OPEN TOPIC, TENURE TRACK, FOR WOMEN SCIENTISTS –
The BIH Johanna Quandt Professorships are particularly aimed at women scientists who have developed their own scientific profile after completing their doctorate and who have professional experience at academic institutions outside Germany. With this program, Stiftung Charité and BIH aim to support outstanding women scientists at an early stage of their careers and thereby provide an important impulse for equal op-portunities in the life sciences.
The professorships are open to all topics and may originate from the entire spectrum of life and health sciences relevant for translation. Applicants are expected to submit an original concept for their professorship. An innovative approach towards the inter-action between basic research and clinical and patient-oriented application will be de-cisive.
Each BIH Johanna Quandt professor will be endowed with funding ranging between 1,500,000 and 3,150,000 euros in the first five years. The W2 professorships will be filled on the basis of a joint appointment of BIH and Charité – Universitätsmedizin Berlin, fulfilling the requirements for appointment in accordance with § 100 of the “Berliner Hochschulgesetz” (Berlin Higher Education Law). The appointments are lim-ited once-off to a period of five years with the option of a subsequent tenure track as a W2 or W3 lifetime professorship at BIH, at Charité – Universitätsmedizin Berlin, or at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association.
Women scientists can apply to Stiftung Charité until June 24, 2019. Further information can be found at
Stiftung Charité is an independent charitable foundation, endowed in 2005 by entrepreneur Johanna Quandt. With the Private Excellence Initiative Johanna Quandt, Stiftung Charité supports the life sciences in Berlin.
The Charité – Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine combine their strengths in the Berlin Institute of Health (BIH). Its guiding idea is translational research, combined with the comprehensive approach of systems medicine.